Hypothyroidism: Causes, Symptoms, Diagnosis, and Treatment

What Is Hypothyroidism?

Hypothyroidism occurs when the thyroid gland, a two-lobed structure in the anterior neck weighing roughly 20, 30 grams, secretes less T4 (thyroxine) and T3 (triiodothyronine) than the body requires. Every cell in the body carries thyroid hormone receptors. When circulating levels fall, basal metabolic rate drops, heart rate slows, and protein synthesis decreases, producing a recognizable cluster of symptoms. The National Institutes of Health estimates that 4.6% of the U.S. population aged 12 and older has hypothyroidism, with overt disease affecting roughly 0.3% and subclinical disease accounting for the rest [1].

Thyroid hormone production follows a feedback loop: the hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary to secrete thyroid-stimulating hormone (TSH), which then drives T4 and T3 synthesis. In primary hypothyroidism, the gland itself fails, TSH rises, and free T4 falls. In the rare secondary or tertiary forms, the fault lies in the pituitary or hypothalamus, and TSH may be low or normal despite low T4.

The distinction matters clinically. A high TSH plus low free T4 confirms primary hypothyroidism. A low or inappropriately normal TSH with low free T4 points to a central cause requiring pituitary MRI [2].

What Causes Hypothyroidism?

Hashimoto's thyroiditis accounts for 90 to 95% of primary hypothyroidism cases in iodine-sufficient countries [3]. Other causes include prior radioactive iodine therapy for hyperthyroidism, thyroid surgery, external neck radiation, certain medications (lithium, amiodarone, interferon-alpha, checkpoint inhibitors), and, less commonly, iodine deficiency in regions with poor dietary iodine intake.

Hashimoto's Thyroiditis. This autoimmune condition targets thyroid peroxidase (TPO) and thyroglobulin with specific antibodies. Anti-TPO antibodies are detectable in more than 95% of confirmed Hashimoto's patients [3]. The gland may enlarge early (goiter), then atrophy as follicles are destroyed over years. Women are seven times more likely to develop Hashimoto's than men, and peak incidence falls between ages 30 and 50 [4].

Medication-Induced Hypothyroidism. Amiodarone, used to manage atrial fibrillation, contains 37% iodine by weight and causes either hypothyroidism or hyperthyroidism in up to 20% of treated patients depending on baseline iodine status and gland morphology [5]. Checkpoint inhibitors such as pembrolizumab produce thyroid immune-related adverse events in 5 to 10% of patients.

Postpartum Thyroiditis. Up to 10% of women develop transient thyroiditis in the first year after delivery. The typical pattern is a brief hyperthyroid phase at 2 to 4 months, followed by a hypothyroid phase at 4 to 8 months. About 20 to 30% of these women progress to permanent hypothyroidism within seven years [6].

Symptoms of Hypothyroidism

The classic symptom set reflects slowed cellular metabolism. Fatigue and weight gain are the most-cited complaints, but the full picture is broader.

Symptoms range from subtle to disabling and often accumulate slowly over months or years before a diagnosis is made. Common presentations include:

• Cold intolerance and low body temperature
• Constipation, often with abdominal bloating
• Dry skin, brittle nails, and coarse hair or hair loss
• Bradycardia (resting heart rate below 60 bpm in some patients)
• Slowed reflexes with delayed relaxation phase
• Cognitive slowing, poor concentration, and depression
• Elevated LDL cholesterol and triglycerides
• Menstrual irregularities and reduced fertility in women
• Myalgia and joint stiffness

Women experience hypothyroidism at rates three to five times higher than men, and symptoms frequently overlap with perimenopause, depression, and chronic fatigue syndrome [4]. This overlap is one reason that diagnosis is often delayed by 12 to 24 months after symptom onset.

Severe, untreated hypothyroidism can progress to myxedema coma, a life-threatening emergency characterized by hypothermia, altered consciousness, hypoventilation, and cardiovascular collapse. Mortality exceeds 30% even with treatment in hospital [7].

Diagnosing Hypothyroidism: Lab Values That Matter

TSH is the first-line screening test. A single TSH measurement detects over 99% of primary hypothyroid cases when the pituitary axis is intact [2]. The conventional laboratory reference range is roughly 0.5, 4.5 mIU/L, but clinical societies disagree on where to set the treatment threshold.

The American Thyroid Association (ATA) 2014 guidelines define overt hypothyroidism as TSH above the upper limit of normal with a low free T4, and subclinical hypothyroidism as TSH above the upper limit with normal free T4 [8]. The Endocrine Society recommends confirming any elevated TSH with a repeat test four to eight weeks later before initiating treatment in nonpregnant adults, because transient TSH elevations from illness ("sick euthyroid syndrome") are common [9].

Free T4 vs. Total T4. Free T4 is preferred over total T4 because it is not influenced by changes in binding proteins caused by pregnancy, oral contraceptives, or liver disease.

Anti-TPO Antibodies. Testing for anti-TPO antibodies confirms an autoimmune etiology and predicts progression to overt hypothyroidism in subclinical disease. Among patients with subclinical hypothyroidism and positive anti-TPO antibodies, roughly 4.3% progress to overt disease per year [10].

Reverse T3. Reverse T3 is not part of standard diagnostic panels and is not recommended by the ATA for routine evaluation. Its clinical utility remains disputed [8].

Subclinical Hypothyroidism: To Treat or Not?

Subclinical hypothyroidism (TSH 4.5, 10 mIU/L with normal free T4) affects an estimated 4 to 8% of the general population and up to 20% of women over 60 [1]. Whether to treat is one of the more debated questions in endocrinology.

The TRUST trial (N=737, average age 74.4 years) randomized older adults with subclinical hypothyroidism to levothyroxine or placebo and found no difference in hypothyroid symptoms, fatigue, or quality-of-life scores at one year [11]. Based on this and similar data, the ATA and the American College of Physicians generally recommend against routine treatment in adults over 65 with TSH <10 mIU/L unless symptoms are present or cardiovascular risk is elevated [8].

In younger adults (under 65) with TSH persistently above 7, 10 mIU/L, a treatment trial is reasonable, particularly in the presence of symptoms, positive anti-TPO antibodies, dyslipidemia, or pregnancy plans. The decision should be documented as a shared clinical agreement rather than a default.

Levothyroxine: Standard Treatment

Levothyroxine sodium (LT4) is the standard of care. It is the synthetic form of T4 and, in most patients, peripheral conversion to T3 provides adequate active hormone at the cellular level. The standard starting dose for otherwise healthy adults under 60 with complete deficiency is 1.6 mcg/kg of lean body weight per day, rounded to the nearest 12.5 or 25 mcg tablet [8].

Older adults or those with coronary artery disease should start at 25 to 50 mcg per day and titrate up in 12.5 to 25 mcg increments every 6 to 8 weeks. The six-to-eight-week interval is non-negotiable: TSH takes that long to reach a new steady state after a dose change.

Absorption Considerations. LT4 absorption is reduced by calcium carbonate, iron supplements, proton pump inhibitors, and soy. Patients should take levothyroxine 30 to 60 minutes before breakfast or four hours after other medications or supplements [8].

Brand vs. Generic. Small bioavailability differences between LT4 formulations exist. The FDA considers products within the standard 80 to 125% bioavailability range to be bioequivalent, but ATA guidelines recommend consistent use of the same formulation with TSH rechecked six weeks after any brand switch [8].

The American Thyroid Association states: "Thyroid hormone therapy normalizes serum TSH in most patients and is expected to resolve most or all symptoms of hypothyroidism in those patients whose symptoms are attributable to thyroid hormone deficiency." [8]

Combination T4 and T3 Therapy: Who Might Benefit?

Roughly 10 to 15% of patients on adequate LT4 report persistent symptoms despite normal TSH values [12]. For this group, the addition of liothyronine (synthetic T3, LT3) or use of desiccated thyroid extract (DTE, which contains both T4 and T3) is an area of active clinical discussion.

The 2019 ATA task force found insufficient evidence to recommend combination therapy routinely but acknowledged that a trial may be appropriate for patients with persistent symptoms who have a normal or low-normal TSH on LT4 alone, particularly those who prefer DTE after a full informed discussion [8]. One genetic factor gaining attention is a polymorphism in the DIO2 gene (encoding type 2 deiodinase), which may impair conversion of T4 to T3 in peripheral tissues. A 2017 study in Thyroid (N=214) found that patients carrying the Thr92Ala DIO2 variant reported better quality of life and cognitive function on combination therapy than on LT4 alone [13].

A practical decision framework for persistent symptoms on LT4:

1. Confirm TSH is in the lower half of the reference range (0.5, 2.0 mIU/L), not just "normal."
2. Rule out other causes: iron deficiency, vitamin B12 deficiency, sleep apnea, depression, celiac disease (present in 3 to 5% of Hashimoto's patients [4]).
3. Check free T3. A free T3 in the lower third of the reference range with normal TSH may indicate poor peripheral conversion.
4. Consider DIO2 genotyping if available.
5. If above steps do not explain symptoms, discuss a time-limited trial (3 to 6 months) of LT4 plus low-dose LT3 (5 to 10 mcg per day) or a switch to DTE with TSH and free T4 monitoring at weeks 6 and 12.

Hashimoto's Thyroiditis: The Autoimmune Foundation

Hashimoto's is not simply "slow thyroid." It is a chronic autoimmune disease that can cycle between euthyroidism, transient hyperthyroidism (Hashitoxicosis), and progressive hypothyroidism as follicles are destroyed and hormone leaks into the bloodstream [3].

Anti-TPO titers do not directly determine treatment decisions, and no therapy currently reduces antibody levels or reverses the autoimmune process. Selenium supplementation at 200 mcg per day has shown modest reductions in anti-TPO titers in three randomized trials and was summarized in a Cochrane review, but evidence for clinical symptom improvement remains weak [14].

Gluten-free diets are frequently discussed in online patient communities. A 2019 systematic review found insufficient evidence to recommend gluten restriction in Hashimoto's patients without confirmed celiac disease or non-celiac gluten sensitivity [15]. The overlap between Hashimoto's and celiac disease is real (roughly 3 to 5% co-occurrence), so celiac antibody screening is reasonable before advising a major dietary change.

Hyperthyroidism and Graves' Disease: The Other End of the Spectrum

Hypothyroidism and hyperthyroidism are opposites in mechanism but share the same diagnostic starting point: TSH. A suppressed TSH (typically <0.1 mIU/L) with elevated free T4 or free T3 confirms hyperthyroidism. Graves' disease, an autoimmune condition characterized by thyroid-stimulating immunoglobulins (TSI) that mimic TSH at the TSH receptor, is the most common cause, accounting for 60 to 80% of all hyperthyroid cases [16].

Graves' disease produces:

• Diffuse goiter
• Exophthalmos (proptosis) in 25 to 50% of patients
• Pretibial myxedema (uncommon, about 5%)
• Tachycardia, palpitations, and weight loss despite normal or increased appetite
• Heat intolerance and excessive sweating
• Anxiety, irritability, and tremor

Treatment options for Graves' include antithyroid drugs (methimazole is preferred over propylthiouracil except in the first trimester of pregnancy), radioactive iodine (RAI) ablation, and surgery. The 2016 ATA guidelines for hyperthyroidism note that all three approaches are acceptable first-line options and that patient preference, access, and comorbidities should guide the choice [16].

Methimazole is typically started at 10 to 30 mg per day in divided doses. Beta-blockers (propranolol 10 to 40 mg every 6 to 8 hours) control adrenergic symptoms within days while waiting for antithyroid drugs to lower hormone levels over 4 to 8 weeks. The ATA states: "For patients with Graves' hyperthyroidism, we suggest that MMI be used in virtually every patient who chooses antithyroid drug therapy." [16]

After 12 to 18 months of antithyroid drug therapy, approximately 40 to 50% of patients achieve remission, defined as normal TSH and free T4 off medication for at least one year. Predictors of remission include small goiter, low TSI titers at the end of treatment, and TSHR gene variants [16].

Hypothyroidism in Pregnancy

Uncontrolled hypothyroidism in pregnancy carries serious risks: miscarriage, preeclampsia, preterm birth, placental abruption, and impaired fetal neurodevelopment [17]. The fetal thyroid does not produce its own hormones until roughly weeks 18, 20, making maternal T4 supply critical in early gestation.

The Endocrine Society recommends a TSH target <2.5 mIU/L in the first trimester and <3.0 mIU/L in the second and third trimesters for women on LT4 [9]. Women with known hypothyroidism should increase their LT4 dose by 25 to 30% as soon as pregnancy is confirmed, typically by taking two extra doses per week [9]. TSH should be rechecked every four weeks through mid-pregnancy and at least once in the third trimester.

The U.S. Preventive Services Task Force (USPSTF) found insufficient evidence (I statement) to recommend universal thyroid screening in asymptomatic pregnant women in 2015 [18]. However, targeted screening of women with symptoms, prior thyroid disease, Type 1 diabetes, or a family history of autoimmune thyroid disease is standard clinical practice.

Lifestyle, Monitoring, and Long-Term Management

Once stabilized on levothyroxine, most patients need TSH checked every 6 to 12 months. Life events that may require dose adjustments include:

• Pregnancy (increase dose immediately upon confirmed pregnancy)
• Significant weight change (>10% body weight)
• Age over 65 (TSH targets are relaxed to 1, 4 mIU/L to reduce atrial fibrillation and bone loss risk from over-replacement)
• Starting or stopping medications that affect LT4 absorption or metabolism

Nutrition. Iodine deficiency remains the leading cause of hypothyroidism globally [19]. In iodine-sufficient countries like the United States, excess iodine from supplements or kelp products can paradoxically worsen hypothyroidism by inhibiting thyroid hormone synthesis (the Wolff-Chaikoff effect). Adults should stay within the recommended dietary allowance of 150 mcg/day for iodine unless pregnant (220 mcg/day) or lactating (290 mcg/day) [19].

Bone and Cardiovascular Monitoring. Over-replacement with LT4 (TSH <0.1 mIU/L) is associated with a 3-fold increased risk of atrial fibrillation and accelerated bone loss, particularly in postmenopausal women [20]. Annual heart rate and blood pressure review and periodic bone density screening (DEXA) are appropriate for patients who have had suppressed TSH for more than two years.

The 2019 ATA guidelines reinforce that the goal of LT4 therapy is symptom resolution with a TSH in the lower half of the reference range, not simple normalization anywhere in the broad 0.5, 4.5 mIU/L window. Individual TSH set-points vary, and a TSH of 3.8 mIU/L may represent inadequate replacement in a patient whose natural pre-disease TSH was 1.2 mIU/L.